Horne, A.; Payne, A.; Crawford, H.; Dempsey, C.; Mistry, H.; Price, G.; Faivre-Finn, C.
The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy. BioMed 2025, 5, 27.
https://doi.org/10.3390/biomed5040027
AMA Style
Horne A, Payne A, Crawford H, Dempsey C, Mistry H, Price G, Faivre-Finn C.
The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy. BioMed. 2025; 5(4):27.
https://doi.org/10.3390/biomed5040027
Chicago/Turabian Style
Horne, Ashley, Amelia Payne, Harry Crawford, Clare Dempsey, Hitesh Mistry, Gareth Price, and Corinne Faivre-Finn.
2025. "The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy" BioMed 5, no. 4: 27.
https://doi.org/10.3390/biomed5040027
APA Style
Horne, A., Payne, A., Crawford, H., Dempsey, C., Mistry, H., Price, G., & Faivre-Finn, C.
(2025). The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy. BioMed, 5(4), 27.
https://doi.org/10.3390/biomed5040027